Orca Bio raised $250 million in fresh financing to support the commercial launch of its T-cell therapy for complications from allogeneic stem cell transplants. The funds will be used to scale manufacturing, prepare for regulatory submissions and support initial market entry activities for the cell therapy. Management framed the round as financing the transition from clinic to commercial supply and emphasized investments in scalable manufacturing and quality systems. The financing also addresses reimbursement and distribution planning ahead of product availability. Large private rounds like Orca’s reflect investor willingness to underwrite late-stage manufacturing and market-entry risk for cell therapies that have demonstrated clinical benefit in hard-to-treat patient populations.